Since it has been suggested that D1R is highly expressed in the striatum and prefrontal cortex, and is involved in movement and cognition, pharmacologists and the pharmaceutical industry have been striving to develop D1R-subtype selective agonists to alleviate movement disorders and cognitive impairment associated with PD11–14. Here, DRD1 is linked to movement disorder.